Is malignant hyperthermia associated with hyperglycaemia?

F. Altamirano1,2,*, S. Riazi3,*, C. A. Ibarra Moreno3, N. Kraeva3, A. Uryash4, P. D. Allen1,5, J. A. Adams1 and J. R. Lopez1,4,*

1Davis, CA, USA, 2Dallas, TX, USA, 3Toronto, ON, Canada, 4Miami, FL, USA and 5Leeds, UK

*Corresponding author. E-mails: lopezpadrino@icloud.com, joser.lopez@msmc.com

Contributed equally to the study.

Editor—Malignant hyperthermia (MH) is a life-threatening disorder triggered in susceptible individuals primarily by halogenated volatile anaesthetic agents, depolarising neuromuscular blocking agents, or both.1 A fulminant MH crisis is characterised by hyperthermia, skeletal muscle rigidity, tachycardia or arrhythmia, respiratory and metabolic acidosis.2 In most MH susceptible (MHS) patients, the disease remains subclinical until they are exposed to pharmacological triggering agents.3,4 MH is associated with mutations in either SRaj1 or CACNA1S that cause profound alterations in resting intracellular Ca2+ ([Ca2+]i) in skeletal muscle cells, even in the absence of anaesthesia.5,6 An elevated [Ca2+]i may induce alterations in cell signalling in MHS skeletal muscles, producing other complications beyond an MH crisis.

We report an unexpected increased frequency of hyperglycaemia in MHS patients (Fig. 1A). Appropriate research approvals were obtained for both humans (University of Toronto, ON, Canada) and animals (Mount Sinai Medical Center, Miami, FL, USA). We analysed fasting or random concentrations of blood glucose and glycosylated haemoglobin (HbA1c) from an MH database at the MH Investigation Unit of University of Toronto, Canada. The database includes 721 MHS patients who tested positive for MH susceptibility either with the caffeine-halothane contracture test or by carrying a diagnostic MH mutation. Blood glucose and HbA1c were available for 356 patients, and hyperglycaemia (i.e. either fasting blood glucose >100 mg dl−1, or random blood glucose >200 mg dl−1) was detected in 148 MHS patients (42%) (Fig. 1A). MHS patients with hyperglycaemia had a larger contracture response to caffeine and halothane; there was a positive correlation between fasting blood glucose values and the contracture response to both caffeine and halothane in MHS patients (Pearson’s coefficient=0.17 and 0.18, respectively, both P<0.001), suggesting that the severity of [Ca2+]i alterations may correlate with alterations in glucose homeostasis.

To further characterise the glucose impairment observed in MHS patients, we performed glucose tolerance tests (GTTs) in an animal model of MHS (RyR1 R163C−/−) and MH normal (MHN) mice (WT littermates). An intragastric bolus of glucose (2 g kg−1 body weight after overnight fasting) was given by a gavage needle, and blood samples obtained from the tail vein at different time points after glucose administration. Blood glucose concentrations were measured using a glucometer (AlphaTRAK Glucose Meter, Abbott Laboratories, Abbott Park, IL, USA). We observed impaired GTT in MHS mice (Fig. 1B) characterised by a higher basal value for fasting blood glucose (258 vs 107 mg dl−1, P<0.001), and increased peak amplitude (543 vs 258 mg dl−1, n=5 per group, P<0.001). Furthermore, MHS mice had slower glucose clearance than MHN mice at 60, 90, and 120 min. The area under the curve analysis demonstrated that MHS mice had blood glucose 2.2-fold higher than MHN mice (Fig. 1B, insert). Dantrolene pretreatment (2.0 mg kg−1 i.p. for 3 days) in MHS mice normalised GTT to near MHN concentrations (Fig. 1B). These results suggest that the R163C−/− RyR1 mutation, which is causative for MH, causes glucose intolerance likely because of increased resting [Ca2+]i, which can be reversed by dantrolene administration. To elucidate the possible mechanism causing glucose intolerance in MHS skeletal muscle, we isolated myoblasts from neonatal MHN and MHS mouse limb muscle (n=3 per genotype; euthanized sacrificed by cervical dislocation) and differentiated them into mature myotubes to study the insulin response using phosphorylation at Ser473 of Akt, a kinase that mediates insulin actions. Differentiated myotubes were exposed to insulin (100 nM) at different times and then quickly lysed on ice. Using western blot analysis, we found reduced Akt phosphorylation upon insulin stimulation in MHS myotubes compared with MHN (Fig. 1C).

We found that 42% of Canadian patients in this study diagnosed as MHS have hyperglycaemia, which was more than what would be expected in the general population. In fact, the prevalence of diabetes and prediabetes in Canada (in people ≥20 yr old for 2015) are estimated at 0.3% and 22%, respectively (www.diabetes.ca). Furthermore, we found a positive correlation between blood glucose and contracture responses to caffeine and halothane in our MHS cohort. It is well established that skeletal muscle from MHS patients or animals has a lower pharmacological threshold and an exaggerated response to submaximal concentrations of caffeine7 and halothane7 than MHN muscle, tests widely used in the clinical diagnosis of MH susceptibility in humans1 and validated experimentally in muscle from swine8 and mice.9 The molecular and cellular basis for heightened sensitivity to caffeine, halothane, and 4-chloro-m-cresol in MHS muscle appears to be related to elevated [Ca2+]i.10,11 Glucose intolerance was also observed in MHS rodents, which was partially reversed by pretreatment with dantrolene, a specific drug to prevent and treat MH, which reduced [Ca2+]i.12 The impaired Akt phosphorylation upon insulin stimulation found in MHS mice may be one of the reasons why MHS mice have chronic hyperglycaemia.

Skeletal muscle is one of the most important tissue targets for insulin in the regulation of blood glucose, as 75–80% of the glucose removed from the blood goes into skeletal muscle and skeletal muscle insulin resistance is one of the primary characteristics of type 2 diabetes mellitus (T2D).13 MHS individuals have an increased glucose-induced insulin response,14 and in this study, we found higher blood glucose in 42% of MHS patients. Furthermore, we found that MHS skeletal muscle cells have impaired insulin cell signalling evidenced by Akt dysregulation that correlates with altered glucose tolerance in mice. The potential impact of the present findings can be quite broad considering that MH syndrome appears to be not just an...
operating room emergency. More studies are necessary to dissect the molecular mechanism responsible for glucose intolerance in MHS individuals and to determine whether these patients are at higher risk of developing a diabetic disequilibrium.

**Declaration of interest**

The authors declare that they have no conflicts of interest.

**References**


4. Yang T, Esteve E, Pessah IN, Molinski TF, Allen PD, Lopez JR. Elevated resting [Ca(2+)](i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR. Am J Physiol Cell Physiol 2007; 292: C1591–8

Pre-hospital advanced airway management: is quality improvement possible? Comment on Br J Anaesth 2018; 120: 1103–9

K.-C. Hung
Tainan, Taiwan
E-mail: ed102605@gmail.com

Editor—We read with great interest the article by Gellerfors and colleagues1 who described rapid completion of pre-hospital tracheal intubation performed by physician anaesthetists and nurse anaesthetists with a high success rate (98.7%) and a low incidence of complications (10.9%). They further reported that the success rate of tracheal intubation on first attempt using videolaryngoscopy (VL) was higher compared with that using conventional laryngoscopy (92.9% vs 78.6%, P < 0.01). Additionally, intubations after a rapid sequence induction (RSI) of anaesthesia had a higher success rate compared with in-hospital emergency anaesthesia (99.4% vs 98.1%; P = 0.02). Although this could permit clinicians to implement a clinical pathway that improves pre-hospital airway management, some interesting issues from their report require clarification.

First, a previous meta-analysis reported a similar rate of first-pass intubations between VL and direct laryngoscopy (DL) in pre-hospital settings or amongst experienced clinicians.2 Conversely, Gellerfors and colleagues1 demonstrated that the rate of first-pass intubations was higher using VL compared with that using DL amongst experienced clinicians during pre-hospital tracheal intubation. Although a discrepancy in results exists between these studies, Gellerfors and colleagues1 should provide further explanation for this conflicting finding. Interestingly, in their study VL was selected as the intubation device in 41.6% of patients at the first attempt. The possible explanations for the high success rate of first-pass intubations but low utilisation rate for VL would be interesting for readers.

Second, 4.2% of patients (n = 86) received more than two intubation attempts,1 highlighting the need for special advantages during pre-hospital tracheal intubation. Gellerfors and colleagues1 stated that ‘pre-hospital emergency anaesthesia and intubation should at least meet the standards for in-hospital emergency anaesthesia’. Fibreoptic intubation is a common technique that is adopted by anaesthetists when anticipating or encountering cases of difficult intubation; therefore, this airway device should be considered as an airway rescue device for pre-hospital emergency care.

Declaration of interest

The author declares that they have no conflict of interest.

References
